LDS/Medical Tests/Norfentanyl, Urine

Norfentanyl, Urine

Norfentanyl is the primary metabolite of the synthetic opioid fentanyl that was introduced in 1963. Norfentanyl is an inactive compound.

The half-life of norfentanyl is 3-12 hours. Fentanyl abuse has become very popular among drug abusers due to the euphoric nature of its effects and its availability. Long-term abuse of fentanyl can lead to respiratory depression or, in severe cases, coma. Fentanyl is only legally available through prescription.

  • Therapeutic monitoring
  • Postoperative analgesia
  • Monitoring management of chronic pain associated with cancer or other terminal illness
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of Norfentanyl and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic Level: as an inactive metabolite, no therapeutic range is published
Toxic level: >not known

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.   

Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatography. 1985;340:139-72
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 14, Miscellaneous Central nervous System Depressants, 421-434; 2013.
  • Brunton LL, Chabner B, Knollman B, eds. Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.